Q&A: Advocating open source drugs

T. V. Padma

, by Science and Development Network (SciDev.Net)

Brahmachari: "Why should we worry about intellectual property protection for infectious diseases and diseases of the poor?"

Leading geneticist Samir Brahmachari explains why India should kickstart a new ’open source’ approach to drug discovery for diseases like TB.

Samir Brahmachari is one of India’s leading genetics researchers and the director general of India’s Council of Scientific and Industrial Research (CSIR), a network of 38 government laboratories.

Brahmachari is kick-starting an ’open source’ approach to drug discovery, focusing first on tuberculosis (TB). He envisages a system where researchers all over the world work on different areas of drug design and deposit their findings into an open database for others to use and comment on — particularly for infectious diseases that affect the world’s poor. Read more